Lilly Global Giving Puts Power of Philanthropy in Employees' Hands
- Details
- Category: Eli Lilly and Company
For the first time, Eli Lilly and Company (NYSE: LLY) employees worldwide can donate to more than 800 grassroots projects across the globe and have their donations matched by the Eli Lilly and Company Foundation - doubling the value and impact of each employee's charitable contribution.
Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for the support of the Early Infant Diagnosis (EID) Programme.
New Senior Executives appointed at Sanofi
- Details
- Category: Sanofi
Sanofi (EURONEXT : SAN ; NYSE : SNY) announced the appointment of Greg Irace, currently President and CEO of Sanofi's US operations, to the newly created role of Senior Vice President, Global Services.
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
FDA approves new medicine BRILINTA (ticagrelor) for use in the US
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.
Pfizer To Acquire Icagen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen's fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share.
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.
More Pharma News ...
- Novartis delivers strong financial results and four major approvals
- Abbott Confirms Long-Term Commitment to HIV Care
- Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers
- XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
- Roche provides update from FDA hearing on Avastin for metastatic breast cancer
- Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
- Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis